Expanded access experience with anti-CD20 radiolabeled monoclonal antibodies for the treatment of B-cell lymphoma.

被引：0
|
作者：
Dillman, RO
Hurwitz, RR
Lyons, KK
Taketa, RM
Jerjian, KA
Hendrix, C
Holt, A
DeLeon, C
O'Connor, AA
Morrelli, LA
机构：
[1] Hoag Canc Ctr, Newport Beach, CA USA
[2] Hoag Mem Hosp Presbyterian, Newport Beach, CA USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4751
引用
收藏
页码：236B / 236B
页数：1
相关论文
共 50 条
  • [31] Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
    Czuczman, MS
    Grillo-López, AJ
    White, CA
    Saleh, M
    Gordon, L
    LoBuglio, AF
    Jonas, C
    Klippenstein, D
    Dallaire, B
    Varns, C
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 268 - 276
  • [32] B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies
    Bojarczuk, K.
    Siernicka, M.
    Dwojak, M.
    Bobrowicz, M.
    Pyrzynska, B.
    Gaj, P.
    Karp, M.
    Giannopoulos, K.
    Efremov, D. F.
    Fauriat, C.
    Golab, J.
    Winiarska, M.
    LEUKEMIA, 2014, 28 (05) : 1163 - 1167
  • [33] Inhibitors Of B-Cell Receptor Molecules Affect Surface CD20 and Impair Antitumor Activity Of Anti-CD20 Monoclonal Antibodies
    Bojarczuk, Kamil
    Winiarska, Magdalena
    Bobrowicz, Malgorzata
    Dwojak, Michal
    Miazek, Nina
    Zapala, Piotr
    Efremov, Dimitar G.
    Golab, Jakub
    BLOOD, 2013, 122 (21)
  • [34] B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies
    K Bojarczuk
    M Siernicka
    M Dwojak
    M Bobrowicz
    B Pyrzynska
    P Gaj
    M Karp
    K Giannopoulos
    D G Efremov
    C Fauriat
    J Golab
    M Winiarska
    Leukemia, 2014, 28 : 1163 - 1167
  • [35] Treatment of posttransplantation diabetes mellitus with anti-CD20 monoclonal antibodies
    Vandenbosch, K
    Champagne, MA
    Gonthier, M
    Moghrabi, A
    Vachon, MF
    Duval, M
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 64 - 64
  • [36] Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma
    McLinden, Gretchen P.
    Avery, Anne C.
    Gardner, Heather L.
    Hughes, Kelley
    Rodday, Angie M.
    Liang, Kexuan
    London, Cheryl A.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2024, 38 (03) : 1666 - 1674
  • [37] Rituxan™:: Anti CD20 monoclonal antibody for the treatment of lymphoma.
    Grillo-López, AJ
    White, CA
    Dallaire, BK
    Varns, C
    Shen, D
    McClure, A
    EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 746 - 746
  • [38] Anti-CD20 monoclonal antibodies in multiple sclerosis
    Moreno Torres, Irene
    Garcia-Merino, Antonio
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (04) : 359 - 371
  • [39] Anti-CD20 monoclonal antibodies: reviewing a revolution
    Casan, J. M. L.
    Wong, J.
    Northcott, M. J.
    Opat, S.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (12) : 2820 - 2841
  • [40] Mechanisms of killing by anti-CD20 monoclonal antibodies
    Glennie, Martin J.
    French, Ruth R.
    Cragg, Mark S.
    Taylor, Ronald P.
    MOLECULAR IMMUNOLOGY, 2007, 44 (16) : 3823 - 3837
12345